Mirova has held the final close  of Mirova-Eurofideme 4, its fourth equity investment fund dedicated to clean energy projects, as EUR857 million. This significant fundraising can be considered a reward for 17 years of investment in renewable energy and brings the total amount of unlisted assets of Mirova’s energy transition

CVC Capital Partners (CVC) has closed the CVC Growth Partners Fund II (Fund II) with capital commitments of USD1.6 billion, including a sidecar co-investment vehicle. Fund II will continue the same investment strategy as its predecessor fund, investing in high-growth, mid-market companies in the software and technology-enabled business services sectors.

Artist Capital Management, a growth-oriented investment management firm, has raised USD100 million for its first fund, the Artist Esports Edge Fund. The Edge Fund seeks to provide institutional investors with concentrated exposure to leading esports companies. Artist Capital Management takes a theme-driven approach to investment research. The firm believes esports – or

Fried Frank has advised Balderton Capital (Balderton), an early stage venture capital investor, on a new USD400 million VC fund, Balderton VII (the Fund). The Fund was oversubscribed having attracted support from investors internationally. It will primarily invest in European technology companies at Series A-stage. Balderton invests in entrepreneurs building

SK Capital Partners (SK Capital), a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, has held the final close of SKCP Catalyst Fund I (SK Catalyst I) at its hard cap, with limited partner capital commitments of USD400 million. SK Catalyst I will focus on control

Essling Capital continues its unlisted co-investment programme with the launch of its third vintage fund, Essling Co-Invest 3 (ECI 3). The launch of ECI 3 is taking place after completion under the previous fund, launched in 2018 for a total raised of EUR116 million, of an eighth and final investment

Clients of Connection Capital, a specialist private client investment business, have invested in the final close of a North America and Europe-focused lower mid-market private equity fund, run by the highly experienced global team at TriSpan, the New York and London-based private equity manager. As per Connection Capital’s investment model,

Stone Capital and Biosyngen have partnered to establish a USD50 million biopharmaceutical investment Fund in Singapore for the Biosyngen biopharmaceutical technology transfer platform and to incubate companies. Biosyngen has been an angel investment platform for biopharmaceutical projects, who has formed projects with selected early stage technologies after stringent screening process.

TCG, a multi-stage investment firm dedicated to building consumer businesses, has closed its inaugural fund with committed capital of over USD700 million. The fund is led by Peter Chernin, Jesse Jacobs and Mike Kerns and will leverage its three founders’ deep experience helping consumer-focused businesses to identify, invest in and